Apellis Pharmaceuticals News and Activities
Presence
Apellis Pharmaceuticals develops and sells biotechnology medicines for rare and serious diseases. Its products and services focus on eye care and immunology treatments for patients, healthcare providers, and specialty care markets.
Apellis Pharmaceuticals products and services overview:
- Eye care therapies
- Rare disease treatments
- Immunology therapies
- Biotechnology research
- Drug development services
Revenue: ~$800 million
Employees: 900
Headquarters: Waltham, United States (USA)
Apellis Pharmaceuticals is one of the...
Apellis Pharmaceuticals is a company listed under the stock ticker APLS (US).
Acquisition, funding and merger involving Apellis Pharmaceuticals.
- Biogen has announced the acquisition of Apellis Pharmaceuticals (posted on March 31 2026).
Executives
View the org chart displaying its 22 main executives
Most searched biographies at Apellis Pharmaceuticals
- Cedric Francois, Chief Executive Officer and Director
- Stephanie Monaghan O'Brien, Director
- Gerald Chan, Chairman of the Board
Popular executive movements at Apellis Pharmaceuticals
- David Lau has joined the company as West Regional Sales Director (posted on May 11 2026).
- Ardelle Ferris, Senior Director, Market Access, has left the company (posted on March 2 2026).
- Mikael Dolsten has joined the company as Director (posted on March 2 2026).
Create your alert
to follow the executive moves at Apellis Pharmaceuticals.
Biotechnology
Apellis Pharmaceuticals has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Apellis Pharmaceuticals
- Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity | Apellis Pharmaceuticals, Inc.
- Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week | Apellis Pharmaceuticals, Inc.
- Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need | Apellis Pharmaceuticals, Inc.
- Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA) | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit | Apellis Pharmaceuticals, Inc.
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 | Apellis Pharmaceuticals, Inc.
- Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Apellis Pharmaceuticals, Inc.
- Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results | Apellis Pharmaceuticals, Inc.
- View more press releases Close
Social media about Apellis Pharmaceuticals
- Apellis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Apellis Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
